Sujal Shah, CymaBay CEO (Credit: Jeff Rumans)
September 7, 2023 10:26 AM EDTUpdated 11:00 AM
R&D

CymaBay meets pri­ma­ry, key sec­ondary end­points in PhI­II liv­er tri­al

Paul Schloesser

Associate Editor

CymaBay Ther­a­peu­tics’ lead can­di­date met the pri­ma­ry end­point and key sec­ondary end­points in a Phase III tri­al for a liv­er dis­ease, set­ting the stage for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times